M
Medlumics
Medlumics is a Madrid-based (Tres Cantos) medical device company founded in 2009 that developed AblaView, a cardiac ablation catheter system guided in real time by optical coherence tomography (OCT) tissue sensing, for treating atrial fibrillation; it later moved to a pulsed-field ablation version and published first-in-human results in 2025. It raised roughly $70M across rounds up to a €14M Series E co-led by Asabys Partners, VI Partners and CDTI Innvierte. Medlumics SL is in liquidation.
SectorsMedical Devices, Healthtech, Cardiology, Photonics, Deeptech
Start-up MapHealthtech & Bio › Medical devices & surgical hardware
Founders
E
Eduardo Margallo Balbás
Co-founder and former CEO/COO
J
José Luis Rubio Guivernau
Co-founder and former CTO
Global models 5
KKardium
Canada · www.kardium.com ↗
Develops a single-shot pulsed-field ablation catheter with integrated tissue sensing and mapping for atrial fibrillation, sold to hospital electrophysiology labs.
~$500MComparable
A
Acutus Medical
United States · www.acutus.com ↗
Venture-backed AF ablation company that combined catheter-based cardiac imaging and mapping with ablation catheters sold to EP labs before its IPO.
~$270MComparable
GGalvanize Therapeutics
United States · www.galvanizetx.com ↗
Builds pulsed-field energy ablation systems, including catheters for cardiac arrhythmias, sold as capital equipment plus disposables to hospitals.
~$200MComparable
AAdagio Medical
United States · www.adagiomedical.com ↗
Develops cryo- and pulsed-field ablation catheters for atrial fibrillation and ventricular tachycardia, following the same hospital device-plus-disposable model.
~$150MComparable
FFarapulse
United States · www.farapulse.com ↗
Pioneered a pulsed-field ablation catheter system for atrial fibrillation and was acquired by Boston Scientific, the exit path Medlumics targeted.
~$130MComparable
In the same niche 72 others
See all in the Start-ups Map →
AAnaconda Biomed
Sant Cugat del Vallès
Series C (estimated) · €90.1M
IINBRAIN Neuroelectronics
Barcelona
Series B (estimated) · €84.5M
OOverture Life
Madrid
Venture Debt · €71.2M
AAortyx
Barcelona
Series A · €16.9M
NNuubo
Madrid
Series B (estimated) · €16.3M
GGeniova
Madrid
Series A (estimated) · €16.1M
Notes: Most funded first
Investors 12
Open as list →
AAsabys Partners
asabys.com
CCentro para el Desarrollo Tecnológico y la Innovación
www.cdti.es
YYsios Capital
ysioscapital.com
CCriteria Capital Risc
www.criteriaventuretech.com
EEdmond de Rothschild Investment Partners
VVI Partners
CCriteria Bio Ventures
I
Innogest Capital
AAndera Partners
KKurma Partners
SSeroba Life Sciences
MMedTech Innovator
Funding rounds 5
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-07-29 | No stage disclosed | €926K partial: only one investor's ticket was disclosed |
Lead not disclosed
+3 more
|
| 2024-02-13 | No stage disclosed | €990K partial: only one investor's ticket was disclosed |
Lead not disclosed
+3 more
|
| 2020-10-08 | Series E | €18M |
Asabys Partners, VI Partners, CDTI Innvierte
+4 more
|
| 2017-03-20 | Series B | €34.4M |
Edmond de Rothschild Investment Partners
+4 more
|
| 2011-12-01 | Series A | €3.5M |
Ysios Capital
+1 more
|
News
No coverage on record yet.